Staphylococcus aureus costochondritis and chest wall abscess in a COVID-19 patient treated with tocilizumab

Ergenc I., ŞANAL TOPRAK C., ODABAŞI Z.

TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, cilt.67, sa.3, ss.382-385, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 67 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5606/tftrd.2021.8208
  • Dergi Adı: TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.382-385
  • Anahtar Kelimeler: Abscess, chest wall, costochondritis, COVID-19, tocilizumab, SERIOUS INFECTIONS, RISK
  • Marmara Üniversitesi Adresli: Evet

Özet

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.